SciVision Biotech Inc., founded in 2001, is a public company listed on the Taiwan Stock Exchange since 2013 (stock symbol 1786). We are a professional developer and manufacturer of high-end medical device hyaluronic acid products. Our own-developed Cross-Linked Hyaluronic Acid Platform (CHAP) is a breakthrough in the contemporary technology bottleneck, which makes the characteristics of hyaluronic acid products precisely controllable and widely used to produce hyaluronic acid products in different fields.
We uphold the concept and spirit of continuous innovation, based on science, create a better vision for mankind, and help people have health, happiness, and achieve a fulfilling life.
In order to meet the need for internationalization and capacity expansion, SciVision Biotech has two production sites, the Biotechnology 1 (BT1) factory and the Medical Device Plant (MD plant), both located in Kaohsiung Cianjhen Technology Industrial Park. The BT1 factory has one basement and seven floors above ground. It is qualified for Quality Management System (QMS) and ISO 13485 and complies with the US FDA and PIC/s GMP regulations. It is fully equipped with advanced automatic equipment. Excellent quality management systems and production capabilities attract cooperation from global partners.
R & D
Capability
Patented CHAP
Technology
Knowledge and
Experiences
Production
Capability
International
Partnership
The company was established on November 12, 2001.
SciVision Biotech has products in four high-end medical device fields, including HA dermal filler in the facial aesthetic field, absorbable adhesion barrier in the surgery field, synovial fluid supplement for the field of elderly care, and intravesical instillation in the field of urology. We provide comprehensive care for the beauty and health of the human race.
This website uses browser records (Cookies) to provide you with the best experience. The Cookies we use also include third-party Cookies.
For related information, please visit ourprivacy policy. If you choose to continue browsing or close this prompt, you agree to our terms of website use.